Autologous Serum Tears for the Treatment of Ocular Surface Disease Secondary to Systemic Autoimmune Diseases Tayyeba K. Ali M.D. Allister Gibbons M.D. Siamak Zarei-Ghanavati M.D., FICO Carolina Betancurt O.D. Alma Michelle Mas M.D. Victor L. Perez M.D. The authors have no financial interests to disclose, relevant to the topic of this poster.
12
Embed
Autologous Serum Tears for the Treatment of Ocular Surface Disease Secondary to Systemic Autoimmune Diseases Tayyeba K. Ali M.D. Allister Gibbons M.D.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Autologous Serum Tears for the Treatment of Ocular Surface Disease Secondary to
Victor L. Perez M.D.The authors have no financial interests to disclose, relevant to the topic of this poster.
Autologous Serum Tears (AST)
• Effectively treat DES and PED• Low frequency of complications (that all cease once
discontinued)
But, patients with systemic autoimmune disorders have:• Circulating immune-complexes• Systemic medication• These accumulate in the serum and could potentially
lead to local side effects.Harloff S, et al. Epitheliotrophic capacity of serum eye drops from healthy donors versus serum from immunosuppressed patients with rheumatoid arthritis. Klin Monbl Augenheilkd. 2008 Mar;225(3):200-6. Poon AC, et al. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol. 2001 Oct;85(10):1188-97.
Purpose
• To determine the safety and efficacy of autologous serum tears, diluted with normal saline, in patients with systemic autoimmune diseases.
Methods
• Retrospective non-comparative case series
• Inclusion criteria– Systemic autoimmune disease– Serum tear use
• Exclusion Criteria– Serum tear use less than 2 months– Incomplete medical records
Methods• Duration of the study:– Time the patients were using AST– We studied the short term effect– Longer term effects of AST remain to be seen and are
currently being studied.
0 – No improvement1 – Partial improvement2 – Complete improvement 3 – Worsening of condition
Definition of Success
Results• 79 eyes of 40 patients• Mean age: 60 ±14 years (28-89 years)• Sex: 60 % Female
Mean (months)
SD+/-
Range (months)
Follow-up 23 16 2-59AST use 15 13 2-50
SLE
OCP
RA
GVHD
Sjö-gren
0 5 10 15 20 25
2
3
5
14
23
Diagnoses
• Some patients have more than one diagnosis• Sjögren = Sjögren Syndrome; GVHD = Graft Versus host disease; RA = Rheumatoid Arthritis;
In Conclusion• No complications or adverse events were
reported in this series.
• AST are safe and effective as an adjunct treatment in the stepwise approach to the treatment of ocular surface disease, in the context of autoimmune diseases.